Pergolizzi Carola, Lazzeri Chiara, Marianello Daniele, Biuzzi Cesare, Irene Casagli, Puddu Antonella, Bargagli Elena, Bennett David, Catelli Chiara, Luzzi Luca, Montagnani Francesca, Gallegos Francisco Del Rio, Scolletta Sabino, Peris Adriano, Franchi Federico
Department of Medical Science, Surgery and Neurosciences, Cardiothoracic and Vascular Anesthesia and Intensive Care Unit, University Hospital of Siena, 53100 Siena, Italy.
Regional Center for Transplant Coordination, 50100 Florence, Italy.
J Clin Med. 2025 Jul 30;14(15):5380. doi: 10.3390/jcm14155380.
Lung transplantation remains the standard of care for end-stage lung disease, yet a persistent gap exists between donor lung availability and growing clinical demand. Expanding the donor pool and optimising donor lung management are therefore critical priorities. However, no universally accepted management protocols are currently in place. This narrative review examines evidence-based strategies to improve lung utilisation across three donor categories: donors after brain death (DBD), controlled donors after circulatory death (cDCD), and uncontrolled donors after circulatory death (uDCD). A systematic literature search was conducted to identify interventions targeting lung preservation and function, including protective ventilation, recruitment manoeuvres, fluid and hormonal management, and ex vivo lung perfusion (EVLP). Distinct pathophysiological mechanisms-sympathetic storm and systemic inflammation in DBD, ischaemia-reperfusion injury in cDCD, and prolonged warm ischaemia in uDCD-necessitate tailored approaches to lung preservation. In DBD donors, early application of protective ventilation, bronchoscopy, and infection surveillance is essential. cDCD donors benefit from optimised pre- and post-withdrawal management to mitigate lung injury. uDCD donor lungs, uniquely vulnerable to ischaemia, require meticulous post-mortem evaluation and preservation using EVLP. Implementing structured, evidence-based lung management strategies can significantly enhance donor lung utilisation and expand the transplantable organ pool. The integration of such practices into clinical protocols is vital to addressing the global shortage of suitable lungs for transplantation.
肺移植仍然是终末期肺病的标准治疗方法,但供肺的可获得性与不断增长的临床需求之间一直存在差距。因此,扩大供体库和优化供肺管理是至关重要的优先事项。然而,目前尚无普遍接受的管理方案。本叙述性综述探讨了基于证据的策略,以提高三类供体肺的利用率:脑死亡后供体(DBD)、心脏死亡后受控供体(cDCD)和心脏死亡后非受控供体(uDCD)。进行了系统的文献检索,以确定针对肺保存和功能的干预措施,包括保护性通气、肺复张手法、液体和激素管理以及体外肺灌注(EVLP)。不同的病理生理机制——DBD中的交感风暴和全身炎症、cDCD中的缺血再灌注损伤以及uDCD中的长时间热缺血——需要采用量身定制的肺保存方法。对于DBD供体,早期应用保护性通气、支气管镜检查和感染监测至关重要。cDCD供体受益于优化的撤机前和撤机后管理,以减轻肺损伤。uDCD供体肺对缺血特别敏感,需要使用EVLP进行细致的尸检评估和保存。实施结构化的、基于证据的肺管理策略可以显著提高供肺利用率并扩大可移植器官库。将这些做法纳入临床方案对于解决全球适合移植的肺短缺问题至关重要。